Corporate Banner
Satellite Banner
Proteomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Crown Bioscience Passes 1000 Model Mark in PDX Collection for Oncology Drug Discovery

Published: Wednesday, April 23, 2014
Last Updated: Tuesday, April 22, 2014
Bookmark and Share
Size of collection allows for more informed preclinical decision making on prospective drug candidates.

Crown Bioscience, Inc. has announced its HuPrime® PDX (Patient-Derived Xenograft) model collection has now passed the 1,000 individual models mark.

The HuPrime model collection, many of which are maintained ‘in life’, enable drug discovery companies to run Clinical Trial-like studies, or HuTrials™, using human surrogate models in mice. Such a comprehensive and diverse collection of well characterized models offers pharmaceutical and biotech partners a unique tool to improve the selection and development path for promising clinical candidates. This can significantly accelerate research programs, reducing the costs and failure rates of drug candidate development.

Patient-Derived Xenografts (PDX) involve extracting human tumors tissues directly from patients and transplanting them into surrogate immunodeficient mice. These models enable drug development and discovery companies to identify genetic signatures of disease, and discover and validate predictive biomarkers (HuSignature™) via performing human surrogate Phase II-like trials (HuTrials™).

Crown Bioscience has greatly expanded its capacity maintaining hundred of models live and running 10s of large-scale HuTrial™ efficacy studies in parallel, acquiring results in months, as opposed to years, and at a significantly lower cost compared to standard human clinical trials.

In addition to this unique Mouse Clinical Trial capacity, the accumulated HuTrial™ experience together with newly developed trial design and HuSignature™ algorithms, greatly enhances Crown’s ability to help partners obtain vital preclinical information essential to the success of their key clinical trials. By validating efficacy, studying and understanding mechanisms of action and resistance and identifying biomarkers, it is possible to improve the stratification of patient populations that may benefit from treatment regimens before entering the clinic.

Jean-Pierre Wery, President of Crown Bioscience, comments, “Passing the 1,000 model mark is a significant milestone in our mission to deliver the ‘gold standard’ in well-characterized models and services to help reduce the attrition rate of candidate compounds in the clinic, before they enter the clinic. As drug discovery continues to rapidly evolve, there is a growing desire to screen candidates earlier with more patient-relevant disease models. We believe that through using models which more closely reflect the patient situation in the clinic, we can significantly accelerate our client’s research programs by helping them make better informed decisions about which compounds to progress into clinical trials.”

He continues, “Our comprehensive collection of models is continuing to rapidly expand and evolve, supported by our databases which enable our clients to rapidly identify models which best suit their needs. Screening candidates earlier with more patient-relevant disease models is helping improve the selection of candidates that are taken forward into the clinic. Earlier informed decision making and shorter trials are redefining the cost and success rate in drug development and discovery.”

Crown’s unique database of HuPrime models, HuBase™ offers a comprehensive database of genotypic, pharmacological, and clinical data, allowing clients to identify and choose the models that meet their criteria based on gene expression, RNAseq, copy number, response to Standard of Care, and many other criteria.

Crown Bioscience has a global footprint, spanning three major continents in North America, Europe, and Asia Pacific. The company offers a unique collection of ready-to-run, well-validated in vitro and in vivo models, model development expertise, comprehensive drug discovery platforms, and global capacity to help clients quantify the real efficacy and pharmacological profile of their candidates before they move into the clinic.

As the largest supplier of translational oncology services, Crown Bioscience is committed to providing its pharmaceutical and biopharmaceutical customers with specialized techniques and services to help the world-wide research community turn cancer from an incurable into a manageable, chronic disease and discover new targets and therapies in the treatment of metabolic diseases.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Protein-Based “Cancer Signature” Uncovered
Researchers investigated the expression of ribosomal proteins in human tissues and discovered a cancer type specific signature which could be used to predict the progression of the disease.
Predicting Leukaemia Development in Cancer Patients
Biomarker may predict which formerly treated cancer patients will develop highly fatal form of leukemia.
‘NoBody,’ a Microprotein On a Mission
Researchers identify over 400 microproteins encoded in the human genome, one of which clears unneeded genetic material inside cells.
Top 10 Life Science Innovations of 2016
2016 has seen the release of some truly innovative products. To help you digest these developments, The Scientist have listed their top picks for the year.
Largest Resource of Protein-Protein Interactions
Researchers have developed the largest ever database of protein-protein interactions.
Bright Red Fluorescent Protein Created
Scientists have created a bright red, fluorescent protein that could be used to track essential cellular processes.
Protein Self-Regulates Abundance
Researchers have uncovered how a protein, that plays a crucial role in embryonic stem cell renewal, is regulated.
'Lab on the Skin' for Sweat Analysis
Northwestern University researchers develop a low-cost wearable electronic device that collects and analyzes sweat for health monitoring.
Building Better Nanodiscs
Researchers have improved upon the design of nanodiscs that provide an unprecedented view of viral infection.
Breast Cancer Cells Starve for Cystine
Depriving triple negative breast cancer, a treatment-resistant form of breast cancer, of cystine results in cancer cell death.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!